Investigation / Researchs - Revista bionatura

Bionatura
Bionatura
Go to content

Main menu:

Investigation / Researchs

Número > Archivos > Vol 1 No 2 2016 > Investigaciones
Association   of gliadin antibodies, HLA alleles, and schizophrenia in Cuban population patients   

Asociación   de anticuerpos antigliadina, alelos HLA y esquizofrenia en pacientes cubanos    
José   A. Galván1, Hanlet Camacho2, William W. Eaton3,   Marcelo Nazabal2, María E. Fernández de Cossio 2, Isabel  Guillen2, Seidy Pedroso2, Raúl Mendoza4, Annia   Ferrer2, Juan Roca2, Jesús Benitez2, Lidia  Inés Novoa2.  

 

Abstract   
Introduction: Several lines of evidence have suggested an interesting link between gluten ingestion and schizophrenia. For example, increased levels of gliadin  and transglutaminase antibodies have been observed in patients with schizophrenia.    
Methods: To verify these observations we compared the prevalence  of gliadin and transglutaminse antibodies, as well as the presence of the HLA alleles, HLA DQA1*0501-DQB1*02 (DQ2) and HLA-DQA1*0301-DQB1*0302 (DQ8), among patients with schizophrenia and healthy controls. A total of 108 patients with schizophrenia and 60 healthy controls were evaluated. Gliadin antibodies were determined by a visual semiquantitative assay and tissue transglutaminase antibodies were determined both by one-step immunochromatografic assay and ELISA. HLA typing was performed by PCR amplification using sequence-specific primers for each allele.
Results: We found a strong association between the presence of gliadin antibodies and schizophrenia (OR 3.488; 95% CI, 1.43-8.44). However, tissue transglutaminase antibodies were not detected in either group neither by immunochromatograpic or ELISA. No significant association was found for the DQ2 or DQ8 heterodimer and the disease, but a significant positive association between schizophrenia and HLA alleles DQA1*0301 and DQB1*02 was present (OR = 2.80; 95% CI, 1.27-6.17,  and OR = 2.37, 95% CI, 1.24-4.53, respectively).
Conclusions: The present study showed that the presence of gliadin antibodies was not correlated with the presence of HLA DQA1*0301 or DQB1*02 alleles within   the group of patients with schizophrenia. Our study replicates the findings   that anti-gliadin antibodies are associated with schizophrenia but also suggests   that the presence of these antibodies and the HLA alleles DQB1*02 and DQA1*0301 are independently associated with susceptibility to schizophrenia.
Keywords: Celiac disease, gliadin antibodies, tissue transglutaminase antibodies,   HLA, schizophrenia, Cuba.

Resumen   
Introducción: Varias evidencias han sugerido un interesante enlace entre la ingestión de gluten   y la esquizofrenia. Un aumento de los niveles de anticuerpos antigliadina y  transglutaminasa se ha observado en pacientes con esquizofrenia.
Métodos: Se comparó la prevalencia de anticuerpos antigliadina y transglutaminse, así como la presencia de los alelos HLA, HLA DQA1*0501-DQB1 * 02 (DQ2) y HLA-DQA1* 0301-DQB1 * 0302 (DQ8), entre pacientes con esquizofrenia y controles sanos.  Se evaluaron un total de 108 pacientes con esquizofrenia y 60 controles sanos. Los anticuerpos antigliadina se determinaron mediante un ensayo de anticuerpos transglutaminasa tisular y semicuantitativos visuales fueron determinados por el ensayo inmunocromatográfico de un solo paso y ELISA. La tipificación de HLA se realizó mediante amplificación por PCR utilizando cebadores específicos de secuencia para cada alelo.
Resultados: Se encontró una fuerte asociación entre la presencia de anticuerpos de la gliadina y la esquizofrenia (OR 3,488; IC del 95%, 1,43-8,44). Sin embargo, los anticuerpos transglutaminasa tisular no se detectaron en ninguno de los grupos ni por immunocromatografía o ELISA. No se encontró asociación significativa para el DQ2 o DQ8 heterodímero y la enfermedad, sino una asociación positiva significativa entre la esquizofrenia y los alelos HLA DQA1 * 0301 y DQB1 *02 estaba presente (OR = 2,80; IC del 95%,   01/27 a 06/17, y OR = CI 2,37, 95%, 1,24 a 4,53, respectivamente).
Conclusiones: Se demostró que la presencia de anticuerpos de gliadina no se correlacionó con la presencia de HLA DQA1 * 0301 o DQB1 * 02 alelos dentro del grupo de pacientes con esquizofrenia. Nuestro estudio replica los hallazgos de que los anticuerpos anti gliadina están asociados con la esquizofrenia, pero también sugiere que la presencia de estos anticuerpos y la HLA alelos DQB1 * 02 y DQA1 * 0301 están  asociados independientemente con la susceptibilidad a la esquizofrenia.
Palabras clave: enfermedad celíaca, anticuerpos anti gliadina, anticuerpos transglutaminasa tisular, HLA, esquizofrenia, Cuba.

Introduction   
Celiac disease (CD) is one of the most common severe food intolerances in the Western world   affecting, almost 1% of the population. The disease is an autoimmune reaction triggered by gluten ingestion in genetically susceptible children and adults. The conclusive diagnosis of CD is carried out by intestinal biopsy, which provides evidence of the histological changes characteristic of this disease. However,  serological screening methods, such as those detecting gliadin antibodies (AGA) and anti-tissue transglutaminase antibodies (tTGA), have gained attention because  they are cheaper and less invasive.1
CD and Gluten Sensitivity, a reaction of the innate immune system to wheat peptides, have been associated with neurologic and psychiatric disorders including cerebellar ataxia, peripheral neuropathy, epilepsy, dementia, depression and autism.2 Given that the prevalence of schizophrenia is almost 1%, the concurrence between   schizophrenia and celiac disease would be expected to be rare; however a possible association between gluten and schizophrenia has been suggested in reports of sporadic cases, and comparisons between samples of persons with schizophrenia   and healthy comparison groups. 3, 4 But another previous study based   on the screening for specific CD antibodies among patients with schizophrenia suggested that there is no direct association between celiac disease and schizophrenia.5 In addition, some studies reported that psychotic symptoms occur in adult celiac disease, and schizophrenic symptoms can improve after gluten-free diet.6    
A recent study hypothesized that gene-associated susceptibility and environment interaction could importantly contribute to schizophrenia. According to this hypothesis,  gut disorders such as CD can lead to poor nutritional conditions and alteration   in gut permeability; in this scenario, the gut could lose its capacity to block  exogenous psychosis-causing substances that may enter the body promoting the development of schizophrenia and other mental conditions.7 In fact,  CD and schizophrenia are complex disorders that have been reported to share genetic relationships. Susceptibility to CD is genetically determined by possession of specific HLA-DQ2 (DQA1*0501, DQB1*0201) and DQ8 (DQA1*0301, DQB1*0302) alleles located on chromosome 6, in concert with one or more non-HLA linked genes.8  The DQB1 locus has been associated with both celiac disease and schizophrenia.   9
Genetic linkage studies for non-HLA loci in CD and schizophrenia suggest several areas of overlap. Recent studies have also shown susceptibility regions for CD in chromosome 11q23 that overlap with a potential schizophrenia susceptibility region.10  Another study has suggested that gene MY09B on chromosome 19, which encodes  a myosin molecule involved in actin remodeling of epithelial enterocytes, might be associated with an increased risk of developing celiac disease and schizophrenia.11  However, a more recent study found no evidence for association between schizophrenia and Non-HLA CD genes, and suggests that these two conditions do not share any functional overlap.12
The objective of the present study was to compare the prevalence of gliadin antibodies, antitransglutaminse antibodies, and HLA DQA1*0501-DQB1*02 (DQ2) and HLA-DQA1*0301-DQB1*0302 alleles (DQ8) between Cuban patients with schizophrenia and healthy controls.

Methods   
Subjects: The study was carried out to determine the presence of AGA and a tTGA in 108 outpatients with paranoid subtype schizophrenia, recruited at the Neuroscience Center in Havana, Cuba. Patients were evaluated by trained psychiatrists using the Spanish version of the Schedules for Clinical Assessment in Neuropsychiatry,  and were diagnosticated with paranoid schizophrenia according to the fourth  edition of the American Psychiatric Association's Diagnostic and Statistical  Manual of Mental Disorders criteria (DSM-IV).13, 14 There were 72  males and 36 females with average age of 35.44 years. The control group comprised 60 mentally normal volunteers, 31 females and 29 males, 37.61 years-old in average, who had never taken psychotropic drugs or presented any psychiatric disorder as determined by their reported history during the clinical interview and by   structured diagnostic criteria categorized according to DSM-IV criteria. No individual reported to have any first-degree relatives with schizophrenia or psychosis. Individuals from both groups completed a questionnaire exploring  sign and symptoms of celiac disease, and registering sociodemographic, nutritional and health habits items. This research was approved by the Ethics Research Committees  of all institutions involved. Patients and controls had given written informed consent for participation in the study. All subjects included in the study agreed   with the terms of the informed consent before the sample was selected.
Anti-gliadin antibodies detection: AGA were measured by AuBioDOTTM gliadin   (HerberBiotec S.A, La Habana, Cuba) as described in detail elsewhere.15 Briefly, AuBioDOT TM gliadin is a semiquantitative visual immunoassay  based on 8 well opaque-white polystyrene strips coated with wheat gliadin (Sigma,   USA). After incubation with a serum or plasma sample, AGA was detected with   a protein A-gold conjugate probe. Silver ion solution is used to enhance the   reaction, and PBS-Tween washings are included after each step. The intensity   of the color is proportional to the quantity of AGA in the samples. A highly positive control serum and a cutoff standard are used to categorize samples   as negatives or positives.
Anti-transglutaminase antibodies detection: The tTGA were detected in blood by using a fast   one-step immunochromatographic assay (HeberFast Line® anti-transglutaminase,  Heber Biotec S.A, Havana, Cuba) that has been shown to have high sensitivity and specificity for diagnosis of the disease. Details of this assay have been  described elsewhere.16 HeberFast Line® anti-transglutaminase is a qualitative assay and consists of a nitrocellulose strip inserted in a plastic   cassette, which is filled with blood obtained from a finger puncture. After 20 minutes, a positive result consists in signals in both the reactive zone   and the control zone. A signal only in the control zone represents a negative result. The HeberFast Line® anti-transglutaminase assay detects both   IgA and IgG antibodies responses, but cannot distinguish between them. Additionally,   IgA anti-transglutaminase antibodies were determined in serum by ELISA (Celikey  Pharmacia & Upjohn, Freiburg, Germany) using cut-offs values as recommended   by the manufacturer.
DNA Isolation   and HLA Typing: DNA was isolated from whole blood using a Wizard Genomic   DNA Purification Kit (Promega, USA) according to the manufacturer's instructions.  Selected HLA alleles DQ2 (HLA-DQA1*0501-DQB1*02) and DQ8 (HLA-DQA1*3-DQB1*0302)   genotyping, was performed by PCR amplification, using sequence-specific primers  (PCR-SSP), as previously described.17 Primers were obtained from the Department of Oligonucleotide Synthesis at the Center of Genetic Engineering   and Biotechnology (Havana, Cuba) and used at 0.25 µmol/L. Amplified products were analyzed in 3% agarose gels and visualized under a UV transilluminator   after ethidium bromide staining.
Definition of Celiac Disease: CD was defined by a combination of tTGA and HLA   DQ2 or DQ8 positives, as first-line diagnostic criteria, considering the high   negative predictive value of the tTGA and HLA markers for celiac disease. We also considered the presence of CD-associated symptoms and AGA to complement   the first-line diagnostic criteria.
Statistical Analysis: The Fisher exact test was used to compare HLA allele frequencies between patients and controls. A precise correction method for multiple comparisons   was applied using the formula alpha=1-(0.951/N), where N is the number of comparisons one or more of which shows a significant result.18 The ?2 test with Yates' correction was used to compare the positivity for gliadin antibodies   in patients and controls in 2 x 2 tables. Odds ratios with 95% confidence intervals  were also estimated. Statistical significance was considered for p values <0.05  for gliadin antibodies comparisons, and p values <0.017 for HLA alleles associations.  All the analysis was made using the SPSS software version 15. In order to determine   the correlation between the presence of gliadin antibodies and specific HLA   DQ alleles in the group of patients with schizophrenia, the correlation coefficient   Phi (f) was calculated using the Pearson correlation with Yates' correction for continuity implemented in SPSS software version 15. For multiple tests we applied Bonferroni corrections.

Results   
Celiac Disease Symptoms: No symptoms of celiac disease were detected on the basis of the criteria established in the questionnaire. There were also no symptoms   found for other disorders associated with so-called "silent" celiac disease.    
Serological Test: Gliadin antibodies were detected in 34 (31.48%) patients with schizophrenia compared with only in 7 (11.66%) individuals in the control group   (p<0.05). We found a strong association between high levels of gliadin antibodies   and schizophrenia, OR=3.478 (95% CI, 1.433- 8.443) (Table 1), suggesting that   the presence of these antibodies could increase the probability of having schizophrenia more than three times (Table 1). However, no serum sample from patients or controls   was positive for tTGA, as determined both by enzyme-linked immunosorbent assay   and by immunochromatographic.



HLA Typing:  In this study, DQ2 or DQ8 heterodimers were not associated with schizophrenia.  Nonetheless, single alleles DQA1*0301 and DQB1*020 were positively associated   with schizophrenia, indicating that their presence confers disease susceptibility   (OR=2.803, 95% CI: 1.273-6.172; and OR=2.368, 95% CI: 1.237-4.534, respectively). In contrast, association of the HLA allele DQB1*0301 with schizophrenia (p<0.05;   OR=2.357, 95% CI: 1.064-5.221) was not significant after Bonferroni correction.   It is important to emphasize that although the correction for multiple independent comparisons is particularly recommended when more than five significant associations  are found, we preferred to be more conservative and applied it in this case   even for three statistically significant associations (Table 2).



Correlation analysis of anti-gliadin antibodies with HLA DQ chains: In order to determine if the observed association between schizophrenia and HLA alleles   was not the result of a confounding bias, due to the relationship of these HLA   alleles and celiac disease (or associated markers), we test the correlation   between gliadin antibodies and HLA DQ alleles within the group of patients with schizophrenia. In this study sample, the presence of gliadin antibodies was   not correlated with any of the HLA DQ alleles as shown in Table 1II; phi (f) values are close to cero and none of the X2 tests were statistically significant after correction for multiple tests. Only the HLA DQB1*0301 allele   showed weak to modest correlation (phi=0.24, p<0.05) (Table 3).



Discussion   
Schizophrenia  and celiac disease each affect almost 1% of general population worldwide. A similar epidemiological characteristic have been reported for the Cuban population.19A  high prevalence of comorbidity between the two conditions would be unexpected   by chance. However, some epidemiological studies4 and sporadic case   reports3 suggest a possible association. Some studies reported that   psychotic symptoms often occur in adult celiac disease and schizophrenic symptoms  can improve after gluten-free diet.6
In our study we   did not find celiac disease in patients with schizophrenia. But we found a strong   association between high AGA level and schizophrenia in patients as compared   with controls (Table 1). The higher prevalence of AGA in patients with schizophrenia suggests that Gluten Sensitivity confers susceptibility to schizophrenia. It is important to note that in this setting, gliadin antibody prevalence among   individuals of the control group was similar to that reported for larger population   studies: 2-12%.20
Antibodies to   tTG and the HLA markers for CD have high negative predictive value for CD. Since   antibodies to tTG were not found in both groups, and, as well, the fact that   there were no significant differences in the presence of susceptibility genes   for celiac disease in schizophrenia and control subjects, our study suggests   that these patients do not have CD. Therefore, these data suggest a potential connection between gluten and schizophrenia. This is in agreement with others'   results, particularly with a recently published study that also found   that most patients with schizophrenia and elevated AGA titers do not have tTGA   and do not appear to have celiac disease.5, 21 Besides, these authors   argue that sample size in their study was not large enough to exclude the possibility   of celiac-associated-markers (HLA-DQ2/DQ8 genes, tTGA, anti-deamidatedgliadin   antibodies), and thereby celiac disease, being more prevalent in patients with   schizophrenia than in normal healthy individuals. However, our study has more   than six times the sample size of the previously mentioned one but we found   the same results. In another study Cascella et al. reported an increased prevalence   of celiac disease in patients with schizophrenia: 5.4% versus 0.80% in the control   group, based on the presence of tTGA. But curiously they found no differences   in the presence of anti-endomysial antibody between two groups in the same study.5   This last finding seems contradictory since antibodies to endomysial tissue   are highly sensitive and specific; many studies have reported values in the   range of 95-100% for both of these parameters.22
We found an association  between schizophrenia and the presence of alleles DQB1*02 and DQA1*0301, which  is in line with previous reports. 23 Wei and Hemmings7 hypothesized that combinations of some DQB1 alleles and defects of the gene CLDN5, which forms permeability barriers in the gut and in the blood-brain barrier   may confer a susceptibility to schizophrenia. Our data do not support this hypothesis   at least in the context of a similar relationship between anti-gliadin immune   response and the proposed gene-defect in gut barrier function, in the framework   of coexistence of particular HLA DQ alleles. In our data the presence of high   levels of AGA in the serum of patients was independent of the presence of the   alleles DQB1*02 and DQA1*0301. Although high levels of anti-gliadin antibodies   were correlated with the allele DQB1*0301, this allele is not associated with   schizophrenia. These data reinforce our view that the relationship of schizophrenia with high levels of AGA, and these specific DQ alleles associations with schizophrenia   are independent.
Gluten is linked  to neurological harm in patients, both with and without evidence of celiac disease.3, 12 The neurotoxic potential of AGA is a contentious issue. Some authors report an increase of AGA levels in neurological diseases. Pellecchia et al.24  reported the occurrence of high AGA levels in 18.7% of multiple system   atrophy affected-patients and Bushara et al.25 reported 37% and 44% AGA prevalence in patients with hereditary ataxia and Huntington's disease respectively.    
The neurotoxicity   of Gliadin antibodiescould be conditioned by their capacity to gain access to   the central nervous system.6 As a matter of fact, AGA has been found   in the cerebrospinal fluid in patients with gluten sensitivity and neurological   dysfunction. Furthermore, in patients with gluten ataxia, the occurrence of   lymphocytic infiltration of the perivascular space and the neutrophil by CD4  and CD8 T cells has been observed, suggesting the presence of a cell-mediated   response, which in turn may compromise blood-brain barrier and allow the access  of AGA into the central nervous system. 6 On the other hand, AGA   levels may be only a reflection of increased intestinal permeability. If this   function of the gut is altered, some of the environmental factors, for example,   potentially pathogenic components from ingested foods could easily enter the   blood stream through the damaged permeability barrier. Consequently, a disease affecting the brain could be triggered. 26  In this context, it could  be of interest to evaluate gluten peptide presence in cerebrospinal fluid of   patients with schizophrenia.
Some authors suggest   that there is an increased permeability of the gut irrespective of the genetic predisposition to autoimmunity. The passage of gliadin through the gut barrier   could be mediated by receptors. In a recent study, Lammers et al. identified   the chemokine receptor CXCR3 as a receptor for gliadin. Their data suggest that   gliadin binds CXCR3 on epithelial cells and triggers the increase in intestinal   permeability through MyD88-dependent release of zonulin. This protein enables   paracellular passage of gliadin (and possibly other nonself antigens) from the   intestinal lumen to the gut mucosa. 27

Conclusions   
Our results reveal   an association between AGA and schizophrenia. Further studies are needed to   elucidate the clinical consequences of this finding, to clarify mechanisms underlying   potential pathophysiological relationships among gliadin, AGA and schizophrenia,   and to investigate the potential of gluten-free diet as an environmental modifier   of the disease.

References   
1. Fasano A, Araya   M, Bhatnagar S, Cameron D, Catassi C, Dirks M, et al. Celiac Disease Working   Group. Federation of International Societies of Pediatric Gastroenterology,   Hepatology, and Nutrition Consensus report on celiac disease. J Pediatr Gastroenterol   Nutr 2008; 47: 214-9. doi: 10.1097/MPG.0b013e318181afed.
2. Jackson JR,   Eaton WW, Cascella NG, Fasano A, Kelly DL. Neurologic and Psychiatric Manifestations   of Celiac Disease and Gluten Sensitivity. Psychiatr Q; 2012; 83: 91-102. doi:   10.1007/s11126-011-9186-y.
3. Brown JS Jr.   Celiac disease and schizophrenia. Am J Psychiatry. 2012; Sep;169(9):991-2. doi:   10.1176/appi.ajp.2012.12060735.
4. Okusaga O,   Yolken RH, Langenberg P, Sleemi A, Kelly DL, Vaswani D, et al. Elevated gliadin   antibody levels in individuals with schizophrenia, World Journal of Biological   Psychiatry. 2013; 14(7):509-15. doi: 10.3109/15622975.2012.747699.
5. Peleg R, Ben-Zion   ZI, Peleg A, Gheber L, Kotler M, Weizman Z, et al. "Bread madness" revisited:   screening for specific celiac antibodies among schizophrenia patients. Eur Psychiatry.   2004; 19:311-4.
6. Hadjivassiliou   M, Sanders DS, Grünewald RA, Woodroofe N, Boscolo S, Aeschlimann D. Gluten sensitivity:   from gut to brain. Lancet Neurol.2010; 9: 318-30. doi: 10.1016/S1474-4422(09)70290-X.    
7. Wei J, Hemmings   GP. Gene, gut and schizophrenia: the meeting point for the gene-environment   interaction in developing schizophrenia. Med Hypotheses 2005; 64:547-52.
8. Dieterich W,   Esslinger B, Schuppan D. Pathomechanisms in celiac disease. Int Arch Allergy   Immunol 2003; 132:98-108.
9. Schwab SG,   Hallmayer J, Freimann J, Lerer B, Albus M, Borrmann-Hassenbach M, et al. Investigation   of linkage and association/linkage disequilibrium of HLA A-, DQA1, DQB1-, and   DQB1-alleles in 69 sib-pair- and 89 trio families with schizophrenia. Am J Med   Genet 2002; 114:315-20.
10. Debono R,   Topless R, Markie D, Black MA, Merriman TR. Analysis of the DISC1 translocation   partner (11q14.3) in genetic risk of schizophrenia. Genes Brain Behav. 2012   Oct;11(7):859-63. doi: 10.1111/j.1601-183X.2012.00832.x.
11. Jungerius   BJ, Bakker SC, Monsuur AJ, Sinke RJ, Kahn RS, Wijmenga C. Is MYO9B the missing   link between schizophrenia and celiac disease? Am J Med Genet B Neuropsychiatr   Genet 2008; 174:351-355.
12. Law MH, Bradford   M, McNamara N, Gajda A, Wei J. No Association Observed between Schizophrenia   and Non-HLA Coeliac Disease Genes: Integration With the Initial MYO9B Association   With Coeliac Disease. Am J Med Genet B Neuropsychiatr Genet 2011; 156B:709-19.   doi: 10.1002/ajmg.b.31213.
13. Vázquez-Barquero   JL, Gaite L, Artal Simón J, Arenal A, Herrera Castanedo S, Díez Manrique JF,   et al. Development and verification of the Spanish version of the "scanning   system" psychiatric interview ("Questionnaires for clinical evaluation in neuropsychiatry".   Actas Luso Esp Neurol Psiquiatr Cienc Afines 1994; 22:109-20.
14. American Psychiatric   Association. Diagnostic and Statistical Manual of Mental Disorders 1994. 4th   edition. Washington DC, American Psychiatric Press.
15. Garrote JA,   Sorell L, Alfonso P, Acevedo B, Ortigosa L, Ribes-Koninckx C, et al. A novel   visual immunoassay for coeliac diasease screening. Eur J Clin Invest 1999; 29:   697-699.
16. Galván JA,   Acevedo B, Novoa LI, Rubí JA, Torres E, Leal V, et al. Development, validation   and registration of the HeberFast Line® anti-transglutaminase system. Contribution   to the diagnosis of Celiac Disease in Cuba. BiotecnolApl 2008; 25: 66-9.
17. Olerup O,   Aldener A, Fogdell A. HLA-DQB1 and DQA1 typing by PCR amplification with sequence-specific   primers (PCR-SSP) in two tours. Tissue Antigens 1993; 41:119-34.
18. Sham P. Statistics   in Human Genetics. Arnold Applications of Statistics, New York, 1998. Strachan,   T. & Read, A. Human Molecular Genetics. 3rd ed.
19. Galván JA,   Lemos G, Fernández de Cossio ME, Ruenes C, Martínez Y, et al. Silent celiac   disease in a cohort of healthy adults. Autoimmunity 2009; 42: 705-8. doi: 10.3109/08916930903214009.    
20. Freeman HJ.   Neurological disorders in adult celiac disease. Can J Gastroenterol. 2008 Nov;   22(11):909-11.
21. Samaroo D,   Dickerson F, Kasarda DD, Green PH, Briani C, Yolken RH, et al. Novel immune   response to gluten in individuals with schizophrenia. Schizophr Res 2010; 118:248-55.   doi: 10.1016/j.schres.2009.08.009.
22. Rostom A,   Murray JA, Kagnoff, MF. American Gastroenterological Association (AGA) Institute   technical review on the diagnosis and management of celiac disease. Gastroenterology   2006; 131:1981-2002.
23. Gutierrez-Achury   J, Zhernakova A, Pulit SL, Trynka G, Hunt KA, Romanos J, Raychaudhuri S, van   Heel DA, Wijmenga C, de Bakker PI. Fine mapping in the MHC region accounts for   18% additional genetic risk for celiac disease. Nat Genet. 2015 Jun;47(6):577-8.   doi: 10.1038/ng.3268.
24. Pellecchia   MT, Ambrosio G, Salvatore E, Vitale C. Possible gluten sensitivity in multiple   system atrophy. Neurology 2002; 59:1114-5.
25. Bushara KO,   Nance M, Gomez CM. Gliadin antibodies in Huntington disease. Neurology 2004;   6:132-3.
26. Fanciulli   G, Dettori A, Demontis MP, Tomasi PA, Anania V, Delitala G. Gluten exorphin   B5 stimulates prolactin secretion through opioid receptors located outside the   blood-brain barrier. Life Sci 2005; 76:1713-19.
27. Lammers KM,   Lu R, Brownley J, Lu B, Gerard C, Thomas K, Rallabhandi P. Gliadin induces an   increase in intestinal permeability and zonulin release by binding to the chemokine   receptor CXCR3. Gastroenterology 2008 135:194-204. doi: 10.1053/j.gastro.2008.03.023.    

Recibido: 16 de  enero de 2016.
Aprobado: 8 de marzo de 2016.

1 Department of Immunology. Institute of Hematology and Immunology. Havana, Cuba.
2 Inmunodiagnostics and Genomics Division, Center for Genetic Engineering and Biotechnology, Havana, Cuba.
3 Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
4 Neuroscience Center. Havana, Cuba.
Correspondence : José Armando Galván Cabrera, MD, PhD. Institute of Hematology and Immunology. Ave 100 y Perla, Altahabana, Boyeros, Havana, Cuba. CP 10800. Tel (537) 6438268, 6438695. Fax: (537) 6442334. E-mail: jagalvancabrera@gmail.com jagalvan@infomed.sld.cu
Back to content | Back to main menu